Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 261

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Prednisone plus Methotrexate for Polymyalgia Rheumatica: A Randomized, Double-Blind, Placebo-Controlled Trial

Open access
Caporali, Roberto, Cimmino, Marco A., Ferraccioli, Gianfranco, Gerli, Roberto, Klersy, Catherine, Salvarani, Carlo, Montecucco, Carlomaurizio, for the Systemic Vasculitis Study Group of the Italian Society for Rheumatology · 2004 · Annals of Internal Medicine

Abstract

BACKGROUND: Steroids are the standard treatment for polymyalgia rheumatica. The efficacy of the candidate drug methotrexate has not yet been demonstrated in controlled studies. OBJECTIVE: To compare the efficacy and safety of prednisone plus methotrexate and prednisone alone in patients with polymyalgia rheumatica. DESIGN: Multicenter randomized, double-blind, placebo-controlled trial. SETTING: 5 Italian rheumatology clinics. PATIENTS: 72 patients with newly diagnosed polymyalgia rheumatica. MEASUREMENTS: The proportion of patients no longer taking prednisone, the number of flare-ups, and the cumulative prednisone dose after 76 weeks. INTERVENTION: Prednisone dosage (25 mg/d) was tapered to 0 mg/d within 24 weeks and was adjusted if flare-ups occurred. Oral methotrexate (10 mg) or placebo, with folinic acid supplementation (7.5 mg), was given weekly for 48 weeks. RESULTS: Twenty-eight of 32 patients in the methotrexate group and 16 of 30 patients in the placebo group were no longer taking prednisone at 76 weeks (P = 0.003). The risk difference was 34 percentage points (95% CI, 11 to 53 percentage points). Similar results were obtained after adjustment for C-reactive protein level and duration of symptoms in a multivariate model. Fifteen of 32 patients in the methotrexate group and 22 of 30 patients in the placebo group had at least 1 flare-up by the end of follow-up (P = 0.04). The median prednisone dose was 2.1 g in the methotrexate group and 2.97 g in the placebo group (P = 0.03). The rate and severity of adverse events were similar. LIMITATIONS: Follow-up was short, and a high dose of folinic acid and a relatively high starting dosage of prednisone were used. Ten of 72 patients (14%) discontinued treatment or were lost to follow-up. CONCLUSIONS: Prednisone plus methotrexate is associated with shorter prednisone treatment and steroid sparing. It may be useful in patients at high risk for steroid-related toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-141-7-200410050-00005

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 261

Metadata

Authors
Caporali, R., Cimmino, M. A., Ferraccioli, G., Gerli, R., Klersy, C., Salvarani, C., Montecucco, C., & for the Systemic Vasculitis Study Group of the Italian Society for Rheumatology
Venue
Annals of Internal Medicine
Published
2004-10-05
Volume
141
Issue
7
Pages
493-500
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W1983403395
Cited by
261
References
44
FWCI
8.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prednisone plus Methotrexate for Polymyalgia Rheumatica: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-141-7-200410050-00005
The paper
Caporali, R., Cimmino, M. A., Ferraccioli, G., Gerli, R., Klersy, C., Salvarani, C., Montecucco, C., & for the Systemic Vasculitis Study Group of the Italian Society for Rheumatology. (2004). Prednisone plus Methotrexate for Polymyalgia Rheumatica: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-141-7-200410050-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.